Route-To-Market Strategy for new vaccine & CyTB products

At Bilthoven Biologicals

Six of our dedicated consultants were involved in a market research project with Bilthoven Biologicals (BBio), a carve-out of the former Netherlands Vaccine Institute acquired by Serum Institute of India in 2012. Since then, BBio has been focusing predominantly on the production of polio vaccines supporting the WHO’s Global Polio Eradication Initiative. Born out of the visionary efforts of Dr Cyrus Ponnawalla, the Serum Institute of India is the world’s largest producer of vaccines. With a remarkable production of over 1.5 billion doses, they cover a spectrum of vaccines reaching about 65% of children worldwide in about 170 countries.

Our Graduate Consultants were actively involved in an extensive project with BBio, focusing on product and market assessments. Their goal was to formulate a strategy to open up new markets for these vaccines, making these high-quality products more widely accessible. This joint initiative represents a collaborative effort to improve global access and distribution of essential vaccines.

Team Bilthoven Biologicals

Emma Nauta


Maartje Eijssen


David Spaargaren


Sietse Eppenga


Job Vlak


Wessel Goslings


More projects

Aligning Fastned’s Executive Team with Global Strategic Direction

For Fastnet

Strategic Insights for Kongsberg Maritime in the Digital Era

For Kongsberg

Strategic Expansion Analysis for Air Liquide

For Air Liquide

Optimizing ASML’s Re-use Process


Sustainable packaging at Nike

For Nike

What is the best route-to-market strategy for ID&Pay?